-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66

Benzinga·08/12/2026 16:58:22
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.